regardless of positive clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant difficulty from PBMs. Such insurers are frequently creating obstacles to access, like steep cost restrictions and PA that hinder cons